Learn Why The Bull Case For Thermo Fisher Scientific Stock Could Change Following Omics Demand Growth

Quantum BioPharma previously announced a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical research business for a Phase 2 Lucid-MS trial. Thermo Fisher also rolled out new drug development and cell culture solutions and expanded real-world evidence capabilities across oncology and immunology. Thermo Fisher Scientific now sits at the intersection of rising demand for omics, biomarker analytics, and outsourced clinical research services. This trend concentrates more workflow,...